{"filing":{"accession_number":"0001213900-26-063157","cik":"0001788028","ticker":"JSPRW","company_name":"Jasper Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-01","report_date":null,"primary_document":"ea0292909-8k_jasper.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1788028/000121390026063157/ea0292909-8k_jasper.htm"},"events":[{"id":7849,"run_id":6886,"accession_number":"0001213900-26-063157","anchor_item_number":"7.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"summary":"The Board has initiated a \"comprehensive review of strategic alternatives aimed at maximizing shareholder value,\" which signals potential M\u0026A activity, restructuring, or other transformative corporate actions. While the disclosure does not confirm a specific transaction, the announcement of a formal strategic review is material to investors as it indicates the company is actively considering significant changes to its business structure or ownership. This does not fit neatly into the M\u0026A taxonomy (which typically requires entry into, completion, or termination of a transaction) but is clearly material and warrants classification as other_material pending further developments.","company_name":"Jasper Therapeutics, Inc.","ticker":"JSPRW","filing_date":"2026-06-01","form":"8-K","submitted_at":null,"items":[{"id":3220,"accession_number":"0001213900-26-063157","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The Board has initiated a \"comprehensive review of strategic alternatives aimed at maximizing shareholder value,\" which signals potential M\u0026A activity, restructuring, or other transformative corporate actions. While the disclosure does not confirm a specific transaction, the announcement of a formal strategic review is material to investors as it indicates the company is actively considering significant changes to its business structure or ownership. This does not fit neatly into the M\u0026A taxonomy (which typically requires entry into, completion, or termination of a transaction) but is clearly material and warrants classification as other_material pending further developments.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-02T02:44:28.773580+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":3220,"accession_number":"0001213900-26-063157","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The Board has initiated a \"comprehensive review of strategic alternatives aimed at maximizing shareholder value,\" which signals potential M\u0026A activity, restructuring, or other transformative corporate actions. While the disclosure does not confirm a specific transaction, the announcement of a formal strategic review is material to investors as it indicates the company is actively considering significant changes to its business structure or ownership. This does not fit neatly into the M\u0026A taxonomy (which typically requires entry into, completion, or termination of a transaction) but is clearly material and warrants classification as other_material pending further developments.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-02T02:44:28.773580+00:00","company_name":"Jasper Therapeutics, Inc.","ticker":"JSPRW","filing_date":"2026-06-01"}]}